The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TRIMBOW (Emerge Health Pty Ltd)
Product name
TRIMBOW
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
155 working days (255)
Active ingredients
beclometasone dipropionate; formoterol (eformoterol) fumarate dihydrate; glycopyrronium bromide (glycopyrrolate)
Registration type
EOI
Indication
New Combination
TRIMBOW (pressurised inhalation solution) is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA).